Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Entrenas (Pilot Calcifediol), 2020
 
NCT04366908
RCTVitamin Dstandard of careCOVID 19 hospitalizedsome concern
50/26 conclusif
  • inconclusive 88 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
  • demonstrated 97 % decrease in ICU admission (PE) with a moderate degree of certainty due to some concern in risk of bias
Annweiler (GERIA-COVID; regular intake of bolus vitamin D), 2020 OBSVitamin DcontrolCOVID 19 hospitalizedNA
29/32 suggested
  • suggested 93 % decrease in deaths (PE)
  • suggested 92 % decrease in death or ventilation
Annweiler (GERIA-COVID; Vitamin D Supplementation After COVID-19 Diagnosis), 2020 OBSVitamin DcontrolCOVID 19 hospitalizedNA
16/32 inconclusive

    COVID-19 mild to moderate meta-analysis

    Rastogi, 2020
     
    NCT04459247
    RCTVitamin DplaceboCOVID-19 mild to moderateNA
    16/24 suggested
    • suggested 5.3-fold increase in PCR-negative conversion (PE)
    Espitia-Hernandez, 2020 NRaVitamin Dstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
    28/7 suggested
    • suggested 714.0-fold increase in PCR-negative conversion

    COVID-19 severe or critically meta-analysis

    Murai, 2020
     
    NCT04449718
    RCTVitamin DplaceboCOVID-19 severe or criticallysome concern
    120/120 inconclusive

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).